Advanced Non-small Cell Lung Cancer, HER2 Mutation Clinical Trials in Aarhus N, Central Jutland

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)